Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P13489
UPID:
RINI_HUMAN
Alternative names:
Placental ribonuclease inhibitor; Ribonuclease/angiogenin inhibitor 1
Alternative UPACC:
P13489; Q8IZK8; Q96FD7; Q9BQ80; Q9UDK6
Background:
The Ribonuclease inhibitor, known as Placental ribonuclease inhibitor or Ribonuclease/angiogenin inhibitor 1, plays a crucial role in cellular mechanisms. It inhibits enzymes such as RNASE1, RNASE2, and ANG, which are vital for RNA metabolism. This protein's ability to regulate these enzymes underscores its importance in maintaining cellular homeostasis and protecting RNA integrity.
Therapeutic significance:
Understanding the role of Ribonuclease inhibitor could open doors to potential therapeutic strategies. Its involvement in inhibiting key enzymes suggests a protective mechanism that could be leveraged in diseases where RNA stability and integrity are compromised.